RAD011 as a Potential Treatment for Hyperphagia in PWS

Study Purpose

SCOUT-015 is a Phase 2/3, double-blind, placebo-controlled study to evaluate the safety and effectiveness of RAD011 synthetic cannabidiol oral solution in people with Prader-Willi Syndrome.  RAD011 is synthetically derived CBD and does not contain THC. This study is looking to enroll approximately 220 individuals between the ages of 8 and 65 years. 

Eligible individuals who complete SCOUT-015 will have the option to enroll in a long-term extension safety study. 

You can learn more about this study in a short webinar recorded in October 2021. Watch the presentation below.

Rad011 Clinical Trial


Download the RAD11 Factsheet

One pager RAD011 SCOUT-015 022422_11Mar2022

Recruitment Criteria

Study Type: Interventional
Eligible Ages: 8-65 years
Other Criteria: 

See the trial listing at clinicaltrials.gov for a full list of inclusion and exclusion criteria.


Trial Details

ClinicalTrials.Gov Id: NCT05098509
Phase: 2/3
Lead Sponsor: Radius
Countries: United States, Canada, others to be determined


This study will be available at the following sites:  

SCOUT15 location list_map_20APR2022_cities_states                                                                       


Contact: Radius Pharmaceuticals
Ellie Ratigan or Nick Poulson
Phone: 617-444-1800
Email: scout015@radiuspharm.com



New Call-to-action

Volunteer Your Time

No matter how big or how small, every effort helps us!